Citations 2

Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares

Journal of Clinical Investigation | July 1, 2025 | Volume: 135 | Issue: 17 | Pages: No page available

10.1172/jci188530 | PMID 40591420

S930 Safety of Ustekinumab Across Approved Adult Indications: Pooled Safety Analysis in Crohn’s Disease, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis Through up to 5 Years

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S441-S441

10.14309/01.ajg.0000777252.35443.aa